2024 Latin America Conference on Lung Cancer (LALCA) - Posters-PP01.55: Innovations in Lipid-Based Nanocomposites for Theranostic Lung Cancer Therapy

Pdf Summary

This study successfully developed a lipid-based nanocomposite incorporating liposomes, iron nanoparticles, a fluorescent probe (BODIPY), and aptamers. These components are designed to specifically target lung cancer cells, enhancing both therapeutic delivery and diagnostic imaging—a concept known as theranostics. The liposomes are decorated with iron oxide nanoparticles, which increase the nanocomposite's specificity and efficacy in targeting lung cancer cells.<br /><br />The results indicate that the incorporation of BODIPY into the hydrophobic regions of the liposomes increases fluorescence, which aids in tracking and imaging. The addition of iron oxide nanoparticles and an aptamer to the liposome formulation resulted in significant changes in size, polydispersity index (PdI), and zeta potential, demonstrating successful integration and interaction of the nanocomposite components.<br /><br />The study conducted MTT assays on H1299 lung cancer cells, showing that the nanocomposite enhances the cytotoxicity of cisplatin—a common chemotherapy drug—by improving its delivery and targeting capabilities. Encapsulating cisplatin in liposomes prevents it from degrading rapidly and clears slowly from the body, thereby enhancing its therapeutic efficacy. The aptamer on the liposome surface specifically binds to lung cancer cells, increasing the precision of drug delivery. Moreover, the presence of BODIPY and iron oxide nanoparticles enables dual imaging, highlighting the nanocomposite's potential for both diagnostic and therapeutic applications.<br /><br />Overall, this research aims to advance lung cancer treatment by providing a more targeted, efficient, and less toxic therapeutic approach. The innovative design of this lipid-based nanocomposite offers promising new opportunities for lung cancer therapy, addressing the urgent need for improved treatment modalities with fewer side effects.

Asset Subtitle

Norma Lucia Buritica Zuluaga

Keywords

lipid-based nanocomposite

liposomes

iron nanoparticles

BODIPY

aptamers

lung cancer

theranostics

cisplatin delivery

dual imaging

targeted therapy